Powering advanced therapies with specialised supply chain

One of the key individual sessions at the Pharma & Med Devices Supply Chain Summit 2025 explored how India’s pharma logistics are adapting to the growing presence of advanced therapies in the healthcare landscape. The session focused on aligning supply chain capabilities with the unique demands of these emerging treatments, where time-sensitive delivery, product stability, and multi-stakeholder coordination play a critical role. 

The session was led by Dhruv Thakkar, VP – Business Development, DHL Supply Chain India. Addressing an audience of industry leaders, logistics experts, and healthcare professionals, the session provided insights into how DHL is responding to the challenges and opportunities presented by unconventional therapies within the Indian market. 

 As advanced therapies become more prevalent, they often demand unconventional logistics solutions ranging from cryopreservation and temperature-controlled transport to strategic partnerships 

Thakkar’s presentation highlighted that as advanced therapies become more prevalent, traditional supply chain models must be reimagined. These therapies often demand unconventional logistics solutions—ranging from cryopreservation and temperature-controlled transport to strategic partnerships across multiple stakeholders. Factors such as therapeutic windows and the rise of personalised treatments further complicate logistics planning. 

The session underscored the need for agility, precision, and innovation in building future-ready supply chains capable of supporting the next generation of healthcare solutions.